



ADULT MEDICATION GUIDELINE	
METARAMINOL	
Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology
This document should be read in conjunction with the Disclaimer .	

Quick Links

Dose	Administration	Monitoring	Pregnancy and Breastfeeding
----------------------	--------------------------------	----------------------------	---

Restrictions

[Formulary: Unrestricted](#)

[HIGH RISK Medication](#) 

Medication Class

Sympathomimetic

Presentation

Ampoule: 10 mg/mL
Pre-filled Syringe: 5mg/ 10mL

Storage

Store at room temperature, below 25°C. Protect from light.

Dose

Treatment of an acute hypotensive state occurring with general or neuraxial anaesthesia
 Refer to KEMH Clinical Guideline: Pain and Anaesthetics: [Adult Resuscitation Drug Protocols](#)

Adjunctive treatment of hypotension due to haemorrhage (hypovolaemia), medication reaction, surgical complications, shock associated with trauma, sepsis or cardiogenic shock
 Refer to KEMH Clinical Guideline: Pain and Anaesthetics: [Adult Resuscitation Drug Protocols](#)

Administration

IV Injection

Inject 0.5 mg bolus diluted (10 mg in 20ml) or from pre-filled syringe and repeat if necessary. Follow with an IV infusion of metaraminol or another vasopressor if required.

IV Infusion

Infuse into large vein, dilute 10mg in 20mL or 30mg in 60mL of sodium chloride 0.9% or glucose 5%.

For more information visit **KEMH Clinical Guideline: Pain and Anaesthetics:** [Adult Resuscitation Drug Protocols](#)

Monitoring

Extravasation may cause tissue necrosis.

Do not stop infusions suddenly, gradual dose reduction is recommended.

Continuous cardiac monitoring is required.

Pregnancy

1st Trimester: Monitoring required

2nd Trimester: Monitoring required

3rd Trimester: Monitoring required

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Breastfeeding

Considered safe to use

Comments

Refer to KEMH Clinical Guideline: Pain and Anaesthetics: [Adult Resuscitation Drug Protocols](#)

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

KEMH Clinical Guideline: Pain and Anaesthetics: [Adult Resuscitation Drug Protocols](#)

[Lidocaine \(lignocaine\) infusion: Intravenous](#)

[Neuraxial analgesia \(including epidural, intrathecal morphine\)](#)

[Caesarean birth](#)

[WNHS Anaesthesia and Pain Medicine Guidelines](#)

WNHS Pharmaceutical and Medicines Management Guidelines:

[High risk medicines](#)

References

Australian Medicines Handbook. Metaraminol. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2022 [cited 2022 May 10]. Available from: <https://amhonline.amh.net.au/>

MIMS Australia. Metaraminol GH Pharma. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2019 [cited 2022 May 10]. Available from: <https://www.mimsonline.com.au>

MIMS Australia. Metaraminol Juno. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2020 [cited 2022 May 10]. Available from: <https://www.mimsonline.com.au>

The Royal Women's Hospital. Metaraminol. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2022 May 11]. Available from: <https://thewomenspbmg.org.au/>

Society of Hospital Pharmacists of Australia. Metaraminol. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2022 [cited 2022 May 10]. Available from: <http://aidh.hcn.com.au>

Keywords	Metaraminol, hypotension, shock, spinal anaesthesia, sympathomimetic				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	07/2015	Last Reviewed:	05/2022	Review Date:	11/05/2025
Endorsed by:	Medicines and Therapeutics Committee			Date:	06/09/2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance		<input checked="" type="checkbox"/>  Std 4: Medication Safety		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.